GlassScriptPhysician profile
Siamak P Etehad
NPI 1184728479
$10,275.86
in general payments reported to CMS, 2019-2025
39 companies · $1,397 in 2025
The $1,397 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,435 · 2020: $1,153 · 2021: $843 · 2022: $997 · 2023: $1,224 · 2024: $3,227 · 2025: $1,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,617 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,189 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,616.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,188.70 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,030.52 | 2021-2025 | |
| Amgen INC. | $710.53 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $690.94 | 2019-2025 | Farxiga, Breztri |
| Merz North America, INC. | $575.85 | 2019 | |
| Lilly USA, LLC | $547.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $531.94 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $485.07 | 2019-2025 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $350.44 | 2019-2025 | Eliquis, Cobenfy, Opdivo |
| Merck Sharp & Dohme LLC | $317.24 | 2020-2024 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.53 | 2022-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.55 | 2019-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $243.13 | 2019-2023 | |
| Pfizer INC. | $205.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $179.01 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $158.66 | 2021-2024 | Linzess |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siamak Etehad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.